Clinical trials: Cancer of the Thyroid
Head and Neck Cancers
Collection Of Tissue, Blood, and Other Specimens From Patients With Head and Neck Tumors To Study the Causes, Diagnosis, Prevention and Treatment of Cancers
This is a protocol to collect tissues, blood, and other specimens from patients with malignant or nonmalignant diseases of the head and neck.
- Trial name
- NCT00580203
- Where
- United States
- Volunteers
- 1,468 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Thyroid Papillary Carcinoma
A Nomogram Model to Predict Central Lymphnode Metastasis in Thyroid Papillary Carcinoma
To establish and validate a suitable and practical nomogram for primary hospitals to predict the risk of central lymph node metastasis (CLNM) among thyroid papillary carcinoma (PTC) patients based on clinical and ultrasound…
- Trial name
- NCT05191927
- Testing
- male
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Lung, Prostate, Breast, Colon, Pancreatic, Renal, Bladder,Thyroid, Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut) Cancer, Cancer of the Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut), Sarcoma Cancer
Optional Sub-study to Intraoperative Imaging With ICG Registry
The primary goal of this optional sub-study is to record what tissues fluoresce in the operating room, and then to identify if these lesions are cancer when the histopathology is performed.
- Conditions
- Lung, Prostate, Breast, Colon, Pancreatic, Renal, Bladder,Thyroid, Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut) Cancer, Cancer of the Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut), Sarcoma Cancer, Cancer of Neuro-onc, Parathyroid, Desmoid Tumors, Melanoma Cancer
- Trial name
- NCT02651246
- Testing
- data collection
- Where
- United States
- Volunteers
- 291 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Haematological Malignancy, Melanoma
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
This clinical trial is looking at a combination of drugs called vemurafenib and cobimetinib. Vemurafenib is approved as standard of care for adult patients with unresectable or metastatic melanoma.
- Conditions
- Haematological Malignancy, Melanoma, Thyroid Cancer, Papillary, Ovarian Neoplasms
- Trial name
- DETERMINE (NCT05768178)
- Testing
- Vemurafenib, Cobimetinib
- Where
- 16 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Refractory Hurthle Cell Thyroid Cancer
Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
This randomized phase II trial studies the effects, good and bad, of using everolimus along with sorafenib tosylate versus sorafenib tosylate alone in treating patients with advanced radioactive iodine refractory thyroid cancer.
- Trial name
- NCT02143726
- Testing
- sorafenib, everolimus
- Where
- 21 sites in United States
- Volunteers
- 35 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Cancer, Cancer Metastatic
The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors
The purpose of this prospective, interventional, single-arm pilot study is to evaluate whether virtually delivered group-based physical activity is feasible for adolescent and young adult (AYA) cancer survivors.
- Conditions
- Cancer, Cancer Metastatic, Neoplasms, Breast Cancer
- Trial name
- NCT05131815
- Testing
- Virtual group based physical activity (BurnAlong) and Social Media Discussion Board
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Cedars-Sinai Medical Center
Differentiated Thyroid Cancer
Nomogram for Predicting Difficult Transoral and Submental Thyroidectomy
No prior studies have stratified the difficulty of transoral and submental thyroidectomy (TOaST). The investigators aimed to investigate preoperative factors as indicators of difficult TOaSTs and to develop a predictive model…
- Trial name
- NCT06671184
- Testing
- Observations on clinicopathological factors influencing the difficulty of surgery
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shanghai 6th People's Hospital
Tumor, Solid, Lung Cancer
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
Independently developed by Sichuan Yingrui Pharmaceutical Technology Co., Ltd., CNSI-Fe is an innovative anti-cancer drug with Fe2+ as the active ingredient, which exerts anti-tumor effects by regulating the ferroptosis pathway.
- Conditions
- Tumor, Solid, Lung Cancer, Pancreas Cancer, Thyroid Cancer
- Trial name
- NCT07433283
- Testing
- Carbon Nanoparticle-Loaded Iron [CNSI-Fe], Carbon Nanoparticle-Loaded Iron
- Where
- 9 sites in China
- Volunteers
- 54 people
- Sponsor
- Sichuan Enray Pharmaceutical Sciences Company
Recurrent Thyroid Cancer
Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer
The goal of this study is to evaluate combined radioactive iodine (RAI, 131-I) and external beam radiotherapy (XRT) to optimize the radiation dose delivered to treat well differentiated thyroid cancers (DTC) with iodine-avid…
- Trial name
- NCT04892303
- Testing
- Combination treatment (CXRPT) of external beam radiation (XRT) plus radioactive iodine (RAI)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Thyroid Nodule
Role of NGS-based ThyroSeq Panel in Cancer Diagnosis in Thyroid Nodules
Recently, targeted next generation sequencing (NGS) platforms have been introduced that allow inexpensive testing for hundreds of mutational hotspots at the same time.
- Trial name
- NCT02352766
- Where
- United States
- Volunteers
- 256 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Thyroid Cancer
Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
The purpose of this study is to find out what effects, good and/or bad, the combination of sorafenib and temsirolimus will have on thyroid cancer.
- Trial name
- NCT01025453
- Testing
- Temsirolimus and Sorafenib
- Where
- 5 sites in United States
- Volunteers
- 37 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Solid Tumor, BRAF V600 Mutation
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
This is a Phase I, First-In-Human, open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer activity of ABM-1310 in adult patients with locally…
- Trial name
- NCT04190628
- Testing
- ABM-1310, Cobimetinib
- Where
- 8 sites in United States
- Volunteers
- 53 people
- Sponsor
- ABM Therapeutics Corporation
Biliary Tract Cancer, Breast Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
- Trial name
- NCT06239194
- Testing
- MDX2001
- Where
- 6 sites in United States
- Volunteers
- 330 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms
Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor
Expanded access for participants with cancer caused by an abnormal RET gene that did not respond/is no longer responding to treatment with a type of drug called a RET inhibitor.
- Trial name
- NCT05225259
- Testing
- LOXO-260
- Sponsor
- Eli Lilly and Company
Papillary Thyroid Cancer, Papillary Thyroid Carcinoma
Active Surveillance and Surgery Outcomes in Low Risk Papillary Thyroid Cancer
This is a prospective, observational, multi-center study examining the long-term outcomes of patients with small, low risk papillary thyroid cancer who offered the choice of active surveillance (close follow-up to monitor for…
- Conditions
- Papillary Thyroid Cancer, Papillary Thyroid Carcinoma, Papillary Microcarcinoma of the Thyroid
- Trial name
- NCT04624477
- Where
- 8 sites in Canada
- Volunteers
- 450 people
- Sponsor
- University Health Network, Toronto
Nodular Goiter, Thyroid Cancer
Elastography in Thyroid Nodules
Nodular goiter is a highly prevalent disease in iodine-deficient areas. Usually nodule assessment includes ultrasonography (US) and fine-needle aspiration (FNA), but some benign nodules can hardly be distinguished from…
- Trial name
- NCT01102127
- Testing
- Elastography
- Where
- Spain
- Volunteers
- 128 people
- Sponsor
- Castilla-León Health Service
Differentiated Thyroid Carcinoma
I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer
Thyroid nodules are a common clinical problem. Epidemiologic studies have shown the prevalence of palpable thyroid nodules to be approximately 5% in women and 1% in men living in iodine-sufficient parts of the world and up to 30%…
- Trial name
- CLERAD-PROBE (NCT01704586)
- Testing
- Radioiodine I-131, I-124
- Where
- 2 sites in Germany
- Volunteers
- 340 people
- Sponsor
- University of Wuerzburg
Symptomatic, Aggressive, Sporadic, Unresectable, Locally, Advanced/Metastatic Medullary Thyroid Cancer (MTC)
Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer
This is a European multinational, multicenter, non-interventional (observational) and prospective study. It is carried on to confirm in real life conditions the benefit/risk of vandetanib (CAPRELSA™) 300 mg, both in RET negative…
- Trial name
- Caprelsa104 (NCT01945762)
- Testing
- Vandetanib 300 mg
- Where
- 8 sites in Belgium, France and 6 more
- Volunteers
- 31 people
- Sponsor
- Genzyme, a Sanofi Company
Hypothyroidism, Thyroid Cancer
Patient-centered Dosage of Levothyroxine
Levothyroxine is the most used thyroid hormone replacement when the thyroid gland is failing. Because dosage adjustment normally takes several months, the investigators have developed a decision support tool (DST) that predicts…
- Conditions
- Hypothyroidism, Thyroid Cancer, Thyroid
- Trial name
- NCT06455371
- Testing
- Decision support tool
- Where
- 3 sites in Norway
- Volunteers
- 240 people
- Sponsor
- University Hospital of North Norway
Iatrogenic Hypocalcemia, Iatrogenic Hypoparathyroidism
Post-thyroidectomy Vocal Cord Paralysis Along With Hypocalcemia: STROBE - Guided Prospective Cohort
In the present study, the severity of recurrent laryngeal nerve injury (RLNI) and hypocalcemia (H) will be followed-up and the probable interrelation between them will be proposed considering the clinical situation of patients…
- Conditions
- Iatrogenic Hypocalcemia, Iatrogenic Hypoparathyroidism, Vocal Cord Paralysis, Vocal Cord Paresis
- Trial name
- NCT04396912
- Testing
- Total thyroidectomy
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Umraniye Education and Research Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.